NCT00568204

Brief Summary

Atomised Methoxymethane-in-Aqua (MEXYN-A) a new topical self-chilled, non-steroidal, non-flammable, pressurised spray which embodies in one simultaneous application, most of the currently recognised and effective chemical, mechanical and thermal anti-pruritic therapies and hydrotherapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
279

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2002

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2002

Completed
3.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2005

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

November 30, 2007

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 5, 2007

Completed
Last Updated

October 17, 2013

Status Verified

October 1, 2013

First QC Date

November 30, 2007

Last Update Submit

October 16, 2013

Conditions

Pruritus

Keywords

pruritus, itching, mexyn-a, clearitch, magicool-plus

Outcome Measures

Primary Outcomes (1)

  • Treating Pruritus

    three days

Secondary Outcomes (1)

  • measuring itch-free period after applying the new treatment, effect on sleep disturbance

    three days

Study Arms (1)

1

EXPERIMENTAL

Mexyn-A

Device: Mexyn-A

Interventions

Mexyn-ADEVICE

Atomised topical self-chilled pressurised spray

Also known as: Clearitch, Itcharret, itchclear, Magicool-Plus
1

Eligibility Criteria

Age5 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients suffering from severe itching due to : Atopic Dermatitis, contact dermatitis, psoriasis, urticaria, xerosis, prickly heat, genital pruritus, chicken pox, aquagenic pruritus, lichen planus, poison ivey, insect bites.
  • Past experience with the use of at least one conventional medication for pruritus or conventional medication for the same disorder patients suffered.

You may not qualify if:

  • Patients who have taken any anti-pruritic drug during the month prior to participation.
  • Patients who have taken drugs for any reason for 2 days prior to participating in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Evangelical Synod Medical Centre

Cairo, Cairo Governorate, 11111, Egypt

Location

MeSH Terms

Conditions

Pruritus

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue DiseasesSkin ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ihab Akhnoukh

    Evangelical Synod Medical Centre

    PRINCIPAL INVESTIGATOR

  • Ashraf Khella

    Harpur Memorial Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 30, 2007

First Posted

December 5, 2007

Study Start

March 1, 2002

Study Completion

September 1, 2005

Last Updated

October 17, 2013

Record last verified: 2013-10

Locations

EG(1)